Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinometostat with Chemotherapy in Newly Diagnosed MLL-Rearranged AML
NCT03724084Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- Nov 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pinometostat in acute myeloid leukemia (AML) (2 cohorts), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 35 days and Complete Response or Complete Response With Incomplete Count Recovery Rate at 3 years. Started Apr 2019; status: terminated.
02
Drugs
pinometostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03724084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724084.